Metabolic Syndrome Prevalence in Renal Cell Cancer Patients

Abstract

Purpose: Renal cell carcinoma (RCC) is increasingly being recognized as a metabolic disease in recent studies.The aim of the present study was to identify the prevalence of metabolic syndrome (MetS) and its associationwith RCC among urologic patients. Materials and <br/><b>Methods</b>: The study included a total of 355 participants (117adult RCC patients and 238 age matched controls) divided into groups, with and without MetS diagnosed usingthe criteria of the American Heart Association/The National Heart Lung and Blood Institute. Groups werecompared statistically and logistic regression analysis was performed to investigate the impact of MetS criteriaon RCC risk. <br/><b>Results</b>: Of the 117 RCC patients, 52 (44.4%) and of the 238 controls, 37 (15.5%) had MetS. Asignificant association (p<0.001) was found between the presence of MetS and RCC (OR: 4.35; 95% CI=2.62-7.21). As the number of MetS components accumulated from 3 to 5, RCC risk increased likewise from 4 to 6times. <br/><b>Conclusions</b>: MetS is more prevalent in RCC patients in Turkey compared to controls. Risk increaseswith the number of coexisting MetS components.